|
May 2
|
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
|
|
Jan 29
|
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
|
|
Jan 19
|
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
|
|
Jan 10
|
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
|
|
Nov 29
|
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
|
|
Nov 28
|
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
|
|
Nov 14
|
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
|
|
Nov 10
|
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
|
|
Nov 7
|
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
|
|
Aug 30
|
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
|
|
Aug 29
|
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
|
|
Aug 22
|
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
|